Press Releases Latest May 09, 2024 Theratechnologies Reports on its Annual Meeting of Shareholders Press Releases Year None202420232022202120202019201820172016201520142013 Jan 02, 2024 Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA Dec 21, 2023 Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement Dec 13, 2023 Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose Nov 24, 2023 Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award Oct 31, 2023 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement Oct 26, 2023 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement Oct 25, 2023 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement Oct 24, 2023 Theratechnologies Announces Operational Update Oct 19, 2023 Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV Oct 16, 2023 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 21 - 30 of 362
Jan 02, 2024 Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
Dec 21, 2023 Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
Dec 13, 2023 Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
Oct 31, 2023 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Oct 26, 2023 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Oct 25, 2023 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
Oct 19, 2023 Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Oct 16, 2023 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon